Join
Live feed
·
INSIDERFilingvia Quantisnow
Cyclacel Pharmaceuticals Inc. logo

Interim CEO Lazar David E. converted options into 194,628,820 shares and sold $5,507,996 worth of shares (194,628,820 units at $0.03) (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CYCC· Cyclacel Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYCC (Cyclacel Pharmaceuticals Inc.) and more on Quantisnow.